{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hasanali ZS"],"funding":["BLRD VA","NIAID NIH HHS","NHLBI NIH HHS","NCI NIH HHS"],"pagination":["e177300"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11141932"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(10)"],"pubmed_abstract":["Multiple myeloma is a largely incurable and life-threatening malignancy of antibody-secreting plasma cells. An effective and widely available animal model that recapitulates human myeloma and related plasma cell disorders is lacking. We show that busulfan-conditioned human IL-6-transgenic (hIL-6-transgenic) NSG (NSG+hIL6) mice reliably support the engraftment of malignant and premalignant human plasma cells, including from patients diagnosed with monoclonal gammopathy of undetermined significance, pre- and postrelapse myeloma, plasma cell leukemia, and amyloid light chain amyloidosis. Consistent with human disease, NSG+hIL6 mice engrafted with patient-derived myeloma cells developed serum M spikes, and a majority developed anemia, hypercalcemia, and/or bone lesions. Single-cell RNA sequenc"],"journal":["JCI insight"],"pubmed_title":["Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice."],"pmcid":["PMC11141932"],"funding_grant_id":["T32 HL007439","R01 AI175185","P30 CA034196","I01 BX004662","R01 AI139123"],"pubmed_authors":["Sheppard NC","Cohen AD","Stadtmauer EA","Susanibar-Adaniya SP","Carroll M","Hasanali ZS","Vogl DT","Garfall AL","Shultz LD","Liu W","Waxman AJ","Dopkin D","Burzenski L","Kadu S","Allman D","Tang Y"],"additional_accession":[]},"is_claimable":false,"name":"Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice.","description":"Multiple myeloma is a largely incurable and life-threatening malignancy of antibody-secreting plasma cells. An effective and widely available animal model that recapitulates human myeloma and related plasma cell disorders is lacking. We show that busulfan-conditioned human IL-6-transgenic (hIL-6-transgenic) NSG (NSG+hIL6) mice reliably support the engraftment of malignant and premalignant human plasma cells, including from patients diagnosed with monoclonal gammopathy of undetermined significance, pre- and postrelapse myeloma, plasma cell leukemia, and amyloid light chain amyloidosis. Consistent with human disease, NSG+hIL6 mice engrafted with patient-derived myeloma cells developed serum M spikes, and a majority developed anemia, hypercalcemia, and/or bone lesions. Single-cell RNA sequenc","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-03T06:48:41.626Z","creation":"2026-05-29T03:06:15.94Z"},"accession":"S-EPMC11141932","cross_references":{"pubmed":["38713510"],"doi":["10.1172/jci.insight.177300"]}}